Tessier-Lavigne Marc
Insider transactions at 3 companies
This page shows all SEC Form 4 filings attributed to Tessier-Lavigne Marc. Form 4 disclosures are required whenever a corporate insider — director, officer, or 10%+ shareholder — buys, sells, or receives company stock. Each row represents a separate reported transaction. All data is sourced directly from the SEC EDGAR public database.
| Company | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| DNLI | Award / Grant | 6,037 | — | — | Jun 3, 2025 | |
| DNLI | Award / Grant | 5,967 | — | — | May 31, 2024 | |
| DNLI | Award / Grant | 4,216 | — | — | Jun 1, 2023 | |
| REGN | Award / Grant | 165 | — | — | Jan 3, 2023 | |
| REGN | Award / Grant | 165 | — | — | Jan 3, 2023 | |
| DNLI | Sale | 20,000 | $30.48 | $609,600 | Nov 23, 2022 | |
| DNLI | Sale | 8,748 | $30.20 | $264,190 | Nov 2, 2022 | |
| REGN | Sale | 1,009 | $689.56 | $695,766 | Sep 29, 2022 | |
| DNLI | Sale | 15,577 | $30.74 | $478,837 | Sep 28, 2022 | |
| DNLI | Sale | 100 | $32.43 | $3,243 | Aug 23, 2022 | |
| DNLI | Sale | 200 | $36.15 | $7,230 | Jul 25, 2022 | |
| DNLI | Disposition | 39,984 | $30.53 | $1,220,712 | Jun 23, 2022 | |
| DNLI | Award / Grant | 5,986 | — | — | Jun 2, 2022 | |
| DNLI | Sale | 8,402 | $33.40 | $280,627 | Mar 23, 2022 | |
| DNLI | Sale | 11,598 | $34.14 | $395,956 | Mar 23, 2022 | |
| REGN | Sale | 7,439 | $690.00 | $5,132,910 | Mar 21, 2022 | |
| REGN | Option Exercise | 7,830 | $376.69 | $2,949,483 | Mar 16, 2022 | |
| REGN | Award / Grant | 191 | — | — | Jan 3, 2022 | |
| DNLI | Sale | 3,602 | $44.38 | $159,857 | Dec 29, 2021 | |
| DNLI | Gift | 200,000 | — | — | Dec 13, 2021 | |
| REGN | Option Exercise | 3,784 | $371.40 | $1,405,378 | Dec 9, 2021 | |
| REGN | Sale | 1,645 | $642.54 | $1,056,978 | Sep 13, 2021 | |
| DNLI | Sale | 700 | $71.06 | $49,742 | Jun 7, 2021 | |
| DNLI | Award / Grant | 2,074 | — | — | Jun 2, 2021 | |
| DNLI | Sale | 37,957 | $60.13 | $2,282,354 | May 24, 2021 | |
| DNLI | Sale | 3,139 | $60.08 | $188,591 | May 3, 2021 | |
| DNLI | Sale | 14,223 | $55.61 | $790,941 | Apr 1, 2021 | |
| DNLI | Sale | 6,011 | $68.50 | $411,754 | Mar 1, 2021 | |
| REGN | Award / Grant | 248 | — | — | Jan 4, 2021 | |
| DNLI | Sale | 400,000 | $26.10 | $10,440,000 | Jun 16, 2020 | |
| REGN | Sale | 900 | $565.35 | $508,815 | May 6, 2020 | |
| REGN | Option Exercise | 5,000 | $57.11 | $285,550 | Feb 13, 2020 | |
| REGN | Award / Grant | 320 | — | — | Jan 2, 2020 | |
| REGN | Award / Grant | 323 | — | — | Jan 2, 2019 | |
| DNLI | C | 25,000 | — | — | Dec 12, 2017 | |
| REGN | Sale | 500 | $595.44 | $297,720 | Aug 5, 2015 | |
| REGN | Sale | 300 | $424.44 | $127,332 | Feb 26, 2015 | |
| 0001594864 | C | 175,000 | — | — | Dec 23, 2014 | |
| REGN | Sale | 3,000 | $352.20 | $1,056,600 | Aug 26, 2014 | |
| AGIO | Purchase | 55,555 | $18.00 | $999,990 | Jul 24, 2013 | |
| REGN | Sale | 500 | $263.50 | $131,750 | May 6, 2013 | |
| 0000318771 | EVP, RESEARCH DRUG DISCOVERY | Disposition | 1,159 | $95.00 | $110,105 | Mar 26, 2009 |
| 0000318771 | EVP, RESEARCH DRUG DISCOVERY | Option Exercise | 18,750 | $53.23 | $998,062 | Jul 16, 2008 |